SNPX News and Press, Synaptogenix Inc. From 07/07/21

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease PR Newswire NEW YORK , July 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerat...

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network PR Newswire NEW YORK , June 24, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing thera...

digicomphoto/iStock via Getty Images Synaptogenyx (SNPX), which has Bryostatin-1 in phase 2b for Alzheimer's disease, is up 26% in afternoon trading. After the closing bell yesterday, a piece from Seeking Alpha contributor DeepValuePlay called the company "the next big thing in Alzheimer's." ...

Gainers: Midatech Pharma (MTP) +33%.Cellect Biotechnology (APOP) +31%.iSun (ISUN) +23%.AGM Group (AGMH) +23%.Synaptogenix (SNPX) +21%9F (JFU) +18%.Capricor Therapeutics (CAPR) +15%.Clearside Biomedical (CLSD) +14%.Rezolute (RZLT) +14%.China Xiangtai Food (PLIN) +13%.Losers: ...

Gainers: Midatech Pharma (MTP) +37%, Cellect Biotechnology (APOP) +30%, Synaptogenix (SNPX) +24%, Clearside Biomedical (CLSD) +16%, Tiziana Life Sciences (TLSA) +16%.Losers: CureVac (CVAC) -44%, Novan (NOVN) -19%, Prothena (PRTA) -14...

Midatech Pharma (MTP) +50% on the successful encapsulation of a biologic using Q-Sphera technology.Cellect Biotechnology (APOP) +40%.Clearside Biomedical (CLSD) +23% after filing registration statement for Quoin Pharma merger.Nano-X Imaging (NNOX) +16% after submits 510(k) appl...

The company's Bryostatin drug is likely to read out positive data in current phase 2, despite its checkered past. Its current market cap is extremely low compared to other companies in this space - suggesting significant upside. A Nasdaq up-listing provides a catalyst as volume is...

Synaptogenix Announces $12.5 Million Private Placement PR Newswire NEW YORK , June 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today an...

Synaptogenix ([[SNPX]] +9.0%) announces an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD").The company has now dosed 58 of its target 100 patients, and se...

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update - Data Safety Monitoring Board confirms Bryostatin-1 Safety PR Newswire NEW YORK , June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmace...